Similarly, Zhu et al demonstrated the safety and feasibility of intravenously administered CD34+, CD133+, and KDR+ EPCs into children with idiopathic pulmonary arterial hypertension (IPAH). The gene discussed is KDR; the disease is idiopathic pulmonary arterial hypertension.